Bausch + Lomb (NYSE:BLCO) Price Target Lowered to $15.00 at Stifel Nicolaus

Bausch + Lomb (NYSE:BLCO) had its price objective reduced by Stifel Nicolaus from $17.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

Other equities analysts have also issued research reports about the stock. Citigroup lowered shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $24.00 to $22.00 in a report on Wednesday, December 11th. Wells Fargo & Company reissued an “equal weight” rating and issued a $15.00 price objective (down from $24.00) on shares of Bausch + Lomb in a research note on Friday, March 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, February 20th. Royal Bank of Canada set a $18.00 price target on Bausch + Lomb in a research note on Thursday, March 27th. Finally, Bank of America reduced their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating for the company in a research report on Thursday, February 20th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $18.82.

Bausch + Lomb Stock Down 7.2 %

Shares of NYSE:BLCO opened at $12.05 on Thursday. The firm has a market cap of $4.25 billion, a P/E ratio of -13.24, a P/E/G ratio of 0.85 and a beta of 0.54. Bausch + Lomb has a 12-month low of $11.94 and a 12-month high of $21.69. The business has a fifty day simple moving average of $15.88 and a 200 day simple moving average of $17.98. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company earned $0.24 earnings per share. Analysts predict that Bausch + Lomb will post 0.74 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Alberta Investment Management Corp increased its stake in Bausch + Lomb by 36.0% in the 4th quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company’s stock valued at $54,328,000 after buying an additional 796,400 shares during the last quarter. Whitebox Advisors LLC grew its holdings in shares of Bausch + Lomb by 16.1% in the fourth quarter. Whitebox Advisors LLC now owns 1,443,101 shares of the company’s stock valued at $26,062,000 after acquiring an additional 199,856 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Bausch + Lomb by 51.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company’s stock valued at $21,996,000 after acquiring an additional 414,138 shares during the last quarter. King Street Capital Management L.P. lifted its holdings in Bausch + Lomb by 55.2% during the fourth quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company’s stock worth $20,522,000 after acquiring an additional 404,256 shares during the period. Finally, Price T Rowe Associates Inc. MD purchased a new position in Bausch + Lomb in the fourth quarter worth $14,122,000. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.